Impact of the adjustment of stratification factors on time-to-event analyses

06/27/2020
by   Madan G. Kundu, et al.
0

In a stratified clinical trial design with time to event end points, stratification factors are often accounted for the log-rank test and the Cox regression analyses. In this work, we have evaluated the impact of inclusion of stratification factors on the power of the stratified log-rank test and have compared the bias and standard error in HR estimate between multivariate and stratified Cox regression analyses through simulation. Results from our investigation suggests that both failing to consider stratification factor in presence of their prognostic effect and stratification with smaller number of events may substantially reduce the power of the log-rank test. Further, the HR estimate from the multivariate Cox analysis is more accurate and precise compared to the stratified Cox analysis. Our findings point towards the necessity of evaluating the impact of stratification factors on the time to event analyses at the time of study design which is presently not a norm.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
09/20/2019

Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis

The log-rank test is most powerful under proportional hazards (PH). In p...
research
01/28/2022

Covariate-Adjusted Log-Rank Test: Guaranteed Efficiency Gain and Universal Applicability

Nonparametric covariate adjustment is considered for log-rank type tests...
research
11/13/2020

The Safe Log Rank Test: Error Control under Optional Stopping, Continuation and Prior Misspecification

We introduce the safe log rank test, a version of the log rank test that...
research
05/19/2020

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching

In confirmatory cancer clinical trials, overall survival (OS) is normall...
research
04/28/2020

Estimation of ascertainment bias and its effect on power in clinical trials with time-to-event outcomes

While the gold standard for clinical trials is to blind all parties – pa...
research
03/03/2022

Censoring and censoring mechanisms in oncology in light of the estimands framework

In oncology clinical trials with time-to-event endpoints, censoring rule...
research
08/18/2020

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) – estimation of adverse event risks

The SAVVY project aims to improve the analyses of adverse event (AE) dat...

Please sign up or login with your details

Forgot password? Click here to reset